Compounded Medications for Cardiovascular Use in Neonatology: an Integrative Review

Overview

Journal Rev Paul Pediatr

Specialty Pediatrics

Date 2022 Sep 14

PMID 36102396

Authors

Lucas Louro Greenhalgh

Marcia Maria Barros Dos Passos

Arthur Lopes Agrizzi

Mariana Sato de Souza Bustamante Monteiro

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the profile of the compounded cardiovascular medicines prescribed in neonatology in Brazil.

Data Source: An integrative bibliographic review was carried out, including studies published in the last 20 years. The used descriptors were: Intensive Care Neonatal, Off-Label Use, Pharmaceutical Preparations, in the databases Virtual Health Library (VHL), PubMed, and Scientific Electronic Library Online (SciELO). Review articles and guidelines were excluded. The quality of the evidence was analyzed, and 10 articles were selected to integrate the study.

Data Synthesis: The profile of routine prescrption in the neonatal unit was evaluated. The main cardiovascular medications prescribed as compounding formulation were: Spironolactone, Captopril, Furosemide, Hydrochlorothiazide, Propranolol, Amiodarone, Nifedipine, Carvedilol, Digoxin, Enalapril, Epinephrine, and Hydralazine. The drugs were obtained from adaptations of dosage forms, through the transformation of capsules or tablets into liquid formulations, as a solution, suspension, or syrup, as well as in the form of solutions prepared from active pharmaceutical ingredients. The compounding of medications made drug therapy possible in neonatology, considering that such medications do not have registration of the oral liquid dosage form in the country, despite being part of the List of Essential Medicines for Children of the Word Health Organization.

Conclusions: It was possible to analyze the profile of compounded cardiovascular medicines prescribed in neonatology in Brazil. The results showed the need for the development of medications suitable for the neonatal population, and the standardization of operational procedures for preparing extemporaneous formulations in neonatology to increase drug safety.

Citing Articles

Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China.

Chen W, Qian H, Sun Q, Zhang S, Zhu L, Wu Y Front Pediatr. 2025; 13:1542348.

PMID: 39967746 PMC: 11832506. DOI: 10.3389/fped.2025.1542348.

A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging.

Bello W, Pezzatti J, Stampfli C, Carrez L, Rudaz S, Sadeghipour F Ther Adv Drug Saf. 2025; 16:20420986251317424.

PMID: 39958972 PMC: 11826846. DOI: 10.1177/20420986251317424.

Evaluation of the type and frequency of extemporaneous formulations dispensed in hospital and community pharmacies.

Ramtoola Z, Catibusic A, Ameen H, Cullen S, Barlow J Explor Res Clin Soc Pharm. 2023; 12:100380.

PMID: 38146320 PMC: 10749281. DOI: 10.1016/j.rcsop.2023.100380.

References

Turner S, Longworth A, Nunn A, Choonara I . Unlicensed and off label drug use in paediatric wards: prospective study. BMJ. 1998; 316(7128):343-5. PMC: 2665567. DOI: 10.1136/bmj.316.7128.343. View

de Souza Jr A, Dos Santos D, Rey L, Medeiros M, Vieira M, Coelho H . Off-label use and harmful potential of drugs in a NICU in Brazil: A descriptive study. BMC Pediatr. 2016; 16:13. PMC: 4722776. DOI: 10.1186/s12887-016-0551-8. View

de Lima Costa H, Costa T, Martins R, Oliveira A . Use of off-label and unlicensed medicines in neonatal intensive care. PLoS One. 2018; 13(9):e0204427. PMC: 6155521. DOI: 10.1371/journal.pone.0204427. View

Jain L . The conundrum of off-label and unlicensed drug usage in neonatology. J Pediatr (Rio J). 2012; 88(6):449-51. DOI: 10.2223/JPED.2243. View

Lee J, Md Redzuan A, Mohamed Shah N . Unlicensed and off-label use of medicines in children admitted to the intensive care units of a hospital in Malaysia. Int J Clin Pharm. 2013; 35(6):1025-9. DOI: 10.1007/s11096-013-9846-0. View

Castro J, Botelho S, Machado T, Martins M, Vieira L, Moreira Reis A . Suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups. Einstein (Sao Paulo). 2018; 16(4):eAO4354. PMC: 6223947. DOI: 10.31744/einstein_journal/2018AO4354. View

Pereira A, Miranda E, de Castilho S, Futuro D, Teixeira L, de Paula G . Magistral drugs in hospitalized newborns and children. Rev Paul Pediatr. 2016; 34(4):403-407. PMC: 5176058. DOI: 10.1016/j.rpped.2016.02.002. View

Carvalho C, Ribeiro M, Bonilha M, Fernandes Jr M, Procianoy R, Silveira R . Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores. J Pediatr (Rio J). 2012; 88(6):465-70. DOI: 10.2223/JPED.2231. View

Souza Jr A, Santos D, Fonseca S, Medeiros M, Batista L, Turner M . Toxic excipients in medications for neonates in Brazil. Eur J Pediatr. 2014; 173(7):935-45. DOI: 10.1007/s00431-014-2272-z. View

10.

OBrien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G . Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine. Int J Mol Sci. 2019; 20(11). PMC: 6600135. DOI: 10.3390/ijms20112688. View

11.

Tramontina M, Heineck I, Santos L . Use of non-formulary drugs in children at a Brazilian teaching hospital: a descriptive study. Pharm Pract (Granada). 2013; 11(1):17-23. PMC: 3780509. DOI: 10.4321/s1886-36552013000100004. View

12.

Nahata M, Allen Jr L . Extemporaneous drug formulations. Clin Ther. 2008; 30(11):2112-9. DOI: 10.1016/j.clinthera.2008.11.020. View

13.

Ernest T, Elder D, Martini L, Roberts M, Ford J . Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol. 2007; 59(8):1043-55. DOI: 10.1211/jpp.59.8.0001. View

14.

Conroy S, McIntyre J . The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med. 2005; 10(2):115-22. DOI: 10.1016/j.siny.2004.11.003. View

15.

Ferreira L, Ibiapina C, Machado M, Fagundes E . [High prevalence of off-label and unlicensed drug prescribing in a Brazilian intensive care unit]. Rev Assoc Med Bras (1992). 2012; 58(1):82-7. View

16.

Magalhaes J, Rodrigues A, Roque F, Figueiras A, Falcao A, Herdeiro M . Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol. 2014; 71(1):1-13. DOI: 10.1007/s00228-014-1768-9. View

17.

Blanco-Reina E, Medina-Claros A, Vega-Jimenez M, Ocana-Riola R, Marquez-Romero E, Ruiz-Extremera A . Drug utilization pattern in children and off-label use of medicines in a pediatric intensive care unit. Med Intensiva. 2015; 40(1):1-8. DOI: 10.1016/j.medin.2014.11.007. View

18.

Lenclen R . [Medication errors in neonatology: a review]. Arch Pediatr. 2007; 14 Suppl 1:S71-7. DOI: 10.1016/s0929-693x(07)80015-7. View

19.

Dos Santos L, Heineck I . Drug utilization study in pediatric prescriptions of a university hospital in southern Brazil: off-label, unlicensed and high-alert medications. Farm Hosp. 2011; 36(4):180-6. DOI: 10.1016/j.farma.2010.12.008. View

20.

Costa P, Rey L, Coelho H . Lack of drug preparations for use in children in Brazil. J Pediatr (Rio J). 2009; 85(3):229-35. DOI: 10.2223/JPED.1896. View